Skip to content

Boston Scientific

NYSE: BSX · USD

Boston Scientific financials

6 charts

Revenue

USD millions

$5,442M
Boston Scientific Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$2,074M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$2,025M; −2.4% vs FY 2009 Q2
FY 2009 Q4$2,079M; +2.7% vs FY 2009 Q3
FY 2010 Q1$1,960M; −5.7% vs FY 2009 Q4
FY 2010 Q2$1,928M; −1.6% vs FY 2010 Q1
FY 2010 Q3$1,916M; −0.6% vs FY 2010 Q2
FY 2010 Q4$2,002M; +4.5% vs FY 2010 Q3
FY 2011 Q1$1,925M; −3.8% vs FY 2010 Q4
FY 2011 Q2$1,975M; +2.6% vs FY 2011 Q1
FY 2011 Q3$1,874M; −5.1% vs FY 2011 Q2
FY 2011 Q4$1,848M; −1.4% vs FY 2011 Q3
FY 2012 Q1$1,866M; +1.0% vs FY 2011 Q4
FY 2012 Q2$1,828M; −2.0% vs FY 2012 Q1
FY 2012 Q3$1,735M; −5.1% vs FY 2012 Q2
FY 2012 Q4$1,821M; +5.0% vs FY 2012 Q3
FY 2013 Q1$1,761M; −3.3% vs FY 2012 Q4
FY 2013 Q2$1,809M; +2.7% vs FY 2013 Q1
FY 2013 Q3$1,735M; −4.1% vs FY 2013 Q2
FY 2013 Q4$1,838M; +5.9% vs FY 2013 Q3
FY 2014 Q1$1,774M; −3.5% vs FY 2013 Q4
FY 2014 Q2$1,873M; +5.6% vs FY 2014 Q1
FY 2014 Q3$1,846M; −1.4% vs FY 2014 Q2
FY 2014 Q4$1,887M; +2.2% vs FY 2014 Q3
FY 2015 Q1$1,768M; −6.3% vs FY 2014 Q4
FY 2015 Q2$1,843M; +4.2% vs FY 2015 Q1
FY 2015 Q3$1,888M; +2.4% vs FY 2015 Q2
FY 2015 Q4$1,978M; +4.8% vs FY 2015 Q3
FY 2016 Q1$1,964M; −0.7% vs FY 2015 Q4
FY 2016 Q2$2,126M; +8.2% vs FY 2016 Q1
FY 2016 Q3$2,105M; −1.0% vs FY 2016 Q2
FY 2016 Q4$2,191M; +4.1% vs FY 2016 Q3
FY 2017 Q1$2,160M; −1.4% vs FY 2016 Q4
FY 2017 Q2$2,257M; +4.5% vs FY 2017 Q1
FY 2017 Q3$2,222M; −1.6% vs FY 2017 Q2
FY 2017 Q4$2,408M; +8.4% vs FY 2017 Q3
FY 2018 Q1$2,379M; −1.2% vs FY 2017 Q4
FY 2018 Q2$2,490M; +4.7% vs FY 2018 Q1
FY 2018 Q3$2,393M; −3.9% vs FY 2018 Q2
FY 2018 Q4$2,561M; +7.0% vs FY 2018 Q3
FY 2019 Q1$2,493M; −2.7% vs FY 2018 Q4
FY 2019 Q2$2,631M; +5.5% vs FY 2019 Q1
FY 2019 Q3$2,707M; +2.9% vs FY 2019 Q2
FY 2019 Q4$2,904M; +7.3% vs FY 2019 Q3
FY 2020 Q1$2,543M; −12.4% vs FY 2019 Q4
FY 2020 Q2$2,003M; −21.2% vs FY 2020 Q1
FY 2020 Q3$2,659M; +32.8% vs FY 2020 Q2
FY 2020 Q4$2,709M; +1.9% vs FY 2020 Q3
FY 2021 Q1$2,752M; +1.6% vs FY 2020 Q4
FY 2021 Q2$3,077M; +11.8% vs FY 2021 Q1
FY 2021 Q3$2,932M; −4.7% vs FY 2021 Q2
FY 2021 Q4$3,127M; +6.7% vs FY 2021 Q3
FY 2022 Q1$3,026M; −3.2% vs FY 2021 Q4
FY 2022 Q2$3,244M; +7.2% vs FY 2022 Q1
FY 2022 Q3$3,170M; −2.3% vs FY 2022 Q2
FY 2022 Q4$3,242M; +2.3% vs FY 2022 Q3
FY 2023 Q1$3,389M; +4.5% vs FY 2022 Q4
FY 2023 Q2$3,599M; +6.2% vs FY 2023 Q1
FY 2023 Q3$3,527M; −2.0% vs FY 2023 Q2
FY 2023 Q4$3,725M; +5.6% vs FY 2023 Q3
FY 2024 Q1$3,856M; +3.5% vs FY 2023 Q4
FY 2024 Q2$4,120M; +6.8% vs FY 2024 Q1
FY 2024 Q3$4,209M; +2.2% vs FY 2024 Q2
FY 2024 Q4$4,561M; +8.4% vs FY 2024 Q3
FY 2025 Q1$4,663M; +2.2% vs FY 2024 Q4
FY 2025 Q2$5,061M; +8.5% vs FY 2025 Q1
FY 2025 Q3$5,065M; +0.1% vs FY 2025 Q2
FY 2025 Q4$5,286M; +4.4% vs FY 2025 Q3
FY 2026 Q1$5,203M; −1.6% vs FY 2025 Q4
FY 2026 Q2$5,442M; +4.6% vs FY 2026 Q1
Jun 30, 2009 through Sep 25, 2026

Free cash flow

USD millions

$1,279M
Boston Scientific Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2$345M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$393M; +13.9% vs FY 2009 Q2
FY 2009 Q4$-416M; −205.9% vs FY 2009 Q3
FY 2010 Q1$-354M; +14.9% vs FY 2009 Q4
FY 2010 Q2$225M; +163.6% vs FY 2010 Q1
FY 2010 Q3$-204M; −190.7% vs FY 2010 Q2
FY 2010 Q4$386M; +289.2% vs FY 2010 Q3
FY 2011 Q1$-166M; −143.0% vs FY 2010 Q4
FY 2011 Q2$307M; +284.9% vs FY 2011 Q1
FY 2011 Q3$297M; −3.3% vs FY 2011 Q2
FY 2011 Q4$266M; −10.4% vs FY 2011 Q3
FY 2012 Q1$146M; −45.1% vs FY 2011 Q4
FY 2012 Q2$355M; +143.2% vs FY 2012 Q1
FY 2012 Q3$226M; −36.3% vs FY 2012 Q2
FY 2012 Q4$307M; +35.8% vs FY 2012 Q3
FY 2013 Q1$110M; −64.2% vs FY 2012 Q4
FY 2013 Q2$345M; +213.6% vs FY 2013 Q1
FY 2013 Q3$193M; −44.1% vs FY 2013 Q2
FY 2013 Q4$189M; −2.1% vs FY 2013 Q3
FY 2014 Q1$139M; −26.5% vs FY 2013 Q4
FY 2014 Q2$220M; +58.3% vs FY 2014 Q1
FY 2014 Q3$290M; +31.8% vs FY 2014 Q2
FY 2014 Q4$361M; +24.5% vs FY 2014 Q3
FY 2015 Q1$-243M; −167.3% vs FY 2014 Q4
FY 2015 Q2$14M; +105.8% vs FY 2015 Q1
FY 2015 Q3$338M; +2314.3% vs FY 2015 Q2
FY 2015 Q4$244M; −27.8% vs FY 2015 Q3
FY 2016 Q1$56M; −77.0% vs FY 2015 Q4
FY 2016 Q2$343M; +512.5% vs FY 2016 Q1
FY 2016 Q3$-102M; −129.7% vs FY 2016 Q2
FY 2016 Q4$299M; +393.1% vs FY 2016 Q3
FY 2017 Q1$2M; −99.3% vs FY 2016 Q4
FY 2017 Q2$117M; +5750.0% vs FY 2017 Q1
FY 2017 Q3$195M; +66.7% vs FY 2017 Q2
FY 2017 Q4$793M; +306.7% vs FY 2017 Q3
FY 2018 Q1$133M; −83.2% vs FY 2017 Q4
FY 2018 Q2$-477M; −458.6% vs FY 2018 Q1
FY 2018 Q3$425M; +189.1% vs FY 2018 Q2
FY 2018 Q4$-87M; −120.5% vs FY 2018 Q3
FY 2019 Q1$287M; +429.9% vs FY 2018 Q4
FY 2019 Q2$201M; −30.0% vs FY 2019 Q1
FY 2019 Q3$381M; +89.6% vs FY 2019 Q2
FY 2019 Q4$506M; +32.8% vs FY 2019 Q3
FY 2020 Q1$-177M; −135.0% vs FY 2019 Q4
FY 2020 Q2$201M; +213.6% vs FY 2020 Q1
FY 2020 Q3$594M; +195.5% vs FY 2020 Q2
FY 2020 Q4$514M; −13.5% vs FY 2020 Q3
FY 2021 Q1$209M; −59.3% vs FY 2020 Q4
FY 2021 Q2$537M; +156.9% vs FY 2021 Q1
FY 2021 Q3$358M; −33.3% vs FY 2021 Q2
FY 2021 Q4$212M; −40.8% vs FY 2021 Q3
FY 2022 Q1$-179M; −184.4% vs FY 2021 Q4
FY 2022 Q2$202M; +212.8% vs FY 2022 Q1
FY 2022 Q3$320M; +58.4% vs FY 2022 Q2
FY 2022 Q4$595M; +85.9% vs FY 2022 Q3
FY 2023 Q1$79M; −86.7% vs FY 2022 Q4
FY 2023 Q2$515M; +551.9% vs FY 2023 Q1
FY 2023 Q3$508M; −1.4% vs FY 2023 Q2
FY 2023 Q4$690M; +35.8% vs FY 2023 Q3
FY 2024 Q1$-15M; −102.2% vs FY 2023 Q4
FY 2024 Q2$658M; +4486.7% vs FY 2024 Q1
FY 2024 Q3$823M; +25.1% vs FY 2024 Q2
FY 2024 Q4$1,179M; +43.3% vs FY 2024 Q3
FY 2025 Q1$354M; −70.0% vs FY 2024 Q4
FY 2025 Q2$1,129M; +218.9% vs FY 2025 Q1
FY 2025 Q3$1,162M; +2.9% vs FY 2025 Q2
FY 2025 Q4$1,013M; −12.8% vs FY 2025 Q3
FY 2026 Q1$171M; −83.1% vs FY 2025 Q4
FY 2026 Q2$1,279M; +648.0% vs FY 2026 Q1

Net margin

%

16.63%
Boston Scientific Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q27.62%
FY 2009 Q3-4.64%
FY 2009 Q4-51.71%
FY 2010 Q1-81.07%
FY 2010 Q25.08%
FY 2010 Q39.92%
FY 2010 Q411.79%
FY 2011 Q12.39%
FY 2011 Q27.39%
FY 2011 Q37.58%
FY 2011 Q45.79%
FY 2012 Q16.06%
FY 2012 Q2-195.73%
FY 2012 Q3-38.27%
FY 2012 Q43.35%
FY 2013 Q1-20.1%
FY 2013 Q27.19%
FY 2013 Q3-0.29%
FY 2013 Q45.88%
FY 2014 Q17.5%
FY 2014 Q20.21%
FY 2014 Q32.33%
FY 2014 Q4-15.85%
FY 2015 Q1-0.06%
FY 2015 Q25.53%
FY 2015 Q3-10.49%
FY 2015 Q4-7.18%
FY 2016 Q110.29%
FY 2016 Q2-9.74%
FY 2016 Q310.83%
FY 2016 Q45.66%
FY 2017 Q113.43%
FY 2017 Q26.47%
FY 2017 Q312.74%
FY 2017 Q4-25.54%
FY 2018 Q112.53%
FY 2018 Q222.29%
FY 2018 Q318.05%
FY 2018 Q415.07%
FY 2019 Q117.01%
FY 2019 Q25.85%
FY 2019 Q34.65%
FY 2019 Q4137.6%
FY 2020 Q10.43%
FY 2020 Q2-7.34%
FY 2020 Q3-5.83%
FY 2020 Q47.75%
FY 2021 Q112.39%
FY 2021 Q26.04%
FY 2021 Q314.29%
FY 2021 Q43.04%
FY 2022 Q13.64%
FY 2022 Q28.01%
FY 2022 Q35.93%
FY 2022 Q44.32%
FY 2023 Q19.27%
FY 2023 Q27.5%
FY 2023 Q314.29%
FY 2023 Q413.53%
FY 2024 Q112.79%
FY 2024 Q27.82%
FY 2024 Q311.12%
FY 2024 Q412.32%
FY 2025 Q114.41%
FY 2025 Q215.71%
FY 2025 Q314.91%
FY 2025 Q412.67%
FY 2026 Q125.74%
FY 2026 Q216.63%

P/E

× · TTM · Daily

17.63×
Boston Scientific P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-02-29—2011-12-31
2012-03-30—2011-12-31
2012-04-30—2011-12-31
2012-05-31—2012-03-31
2012-06-29—2012-03-31
2012-07-31—2012-03-31
2012-08-31—2012-06-30
2012-09-28—2012-06-30
2012-10-31—2012-06-30
2012-11-30—2012-09-30
2012-12-31—2012-09-30
2013-01-31—2012-09-30
2013-02-28—2012-12-31
2013-03-28—2012-12-31
2013-04-30—2012-12-31
2013-05-31—2013-03-31
2013-06-28—2013-03-31
2013-07-31—2013-03-31
2013-08-30—2013-06-30
2013-09-30—2013-06-30
2013-10-31—2013-06-30
2013-11-29—2013-09-30
2013-12-31—2013-09-30
2014-01-31—2013-09-30
2014-02-28—2013-09-30
2014-03-31—2013-09-30
2014-04-30—2013-09-30
2014-05-30—2013-09-30
2014-06-30—2013-09-30
2014-07-31—2013-09-30
2014-08-29—2013-09-30
2014-09-30—2013-09-30
2014-10-31—2013-09-30
2014-11-28—2013-09-30
2014-12-31—2013-09-30
2015-01-30—2013-09-30
2015-02-27—2013-09-30
2015-03-31—2013-09-30
2015-04-30—2013-09-30
2015-05-29—2013-09-30
2015-06-30—2013-09-30
2015-07-31—2013-09-30
2015-08-31—2013-09-30
2015-09-30—2013-09-30
2015-10-30—2013-09-30
2015-11-30—2013-09-30
2015-12-31—2013-09-30
2016-01-29—2013-09-30
2016-02-29—2015-12-31
2016-03-31—2015-12-31
2016-04-29—2015-12-31
2016-05-31—2016-03-31
2016-06-30—2016-03-31
2016-07-29—2016-03-31
2016-08-31—2016-06-30
2016-09-30—2016-06-30
2016-10-31—2016-06-30
2016-11-30—2016-09-30
2016-12-30—2016-09-30
2017-01-31—2016-09-30
2017-02-28—2016-12-31
2017-03-31—2016-12-31
2017-04-28—2016-12-31
2017-05-31—2017-03-31
2017-06-30—2017-03-31
2017-07-31—2017-03-31
2017-08-31—2017-06-30
2017-09-29—2017-06-30
2017-10-31—2017-06-30
2017-11-30—2017-09-30
2017-12-29—2017-09-30
2018-01-31—2017-09-30
2018-02-28—2017-12-31
2018-03-29—2017-12-31
2018-04-30—2017-12-31
2018-05-31—2018-03-31
2018-06-29—2018-03-31
2018-07-31—2018-03-31
2018-08-31—2018-06-30
2018-09-28—2018-06-30
2018-10-31—2018-09-30
2018-11-30—2018-09-30
2018-12-31—2018-09-30
2019-01-31—2018-09-30
2019-02-28—2018-09-30
2019-03-29—2018-09-30
2019-04-30—2018-09-30
2019-05-31—2018-09-30
2019-06-28—2018-09-30
2019-07-31—2018-09-30
2019-08-30—2018-09-30
2019-09-30—2018-09-30
2019-10-31—2018-09-30
2019-11-29—2018-09-30
2019-12-31—2018-09-30
2020-01-31—2018-09-30
2020-02-28—2018-09-30
2020-03-31—2018-09-30
2020-04-30—2018-09-30
2020-05-29—2018-09-30
2020-06-30—2018-09-30
2020-07-31—2018-09-30
2020-08-31—2018-09-30
2020-09-30—2018-09-30
2020-10-30—2018-09-30
2020-11-30—2018-09-30
2020-12-31—2018-09-30
2021-01-29—2018-09-30
2021-02-26—2020-12-31
2021-03-31—2020-12-31
2021-04-30—2020-12-31
2021-05-28—2020-12-31
2021-06-30—2020-12-31
2021-07-30—2020-12-31
2021-08-31—2020-12-31
2021-09-30—2020-12-31
2021-10-29—2020-12-31
2021-11-3049.68×2021-09-30
2021-12-3155.44×2021-09-30
2022-01-3155.99×2021-09-30
2022-02-2857.65×2021-09-30
2022-03-3157.8×2021-09-30
2022-04-2954.96×2021-09-30
2022-05-3153.52×2021-09-30
2022-06-3048.64×2021-09-30
2022-07-2953.57×2021-09-30
2022-08-3152.61×2021-09-30
2022-09-3050.55×2021-09-30
2022-10-3156.26×2021-09-30
2022-11-3059.08×2021-09-30
2022-12-3060.39×2021-09-30
2023-01-3160.36×2021-09-30
2023-02-2860.97×2021-09-30
2023-03-3165.29×2021-09-30
2023-04-2868.02×2021-09-30
2023-05-3198.21×2022-03-31
2023-06-30103.19×2022-03-31
2023-07-3198.91×2022-03-31
2023-08-3193.67×2022-06-30
2023-09-2991.69×2022-06-30
2023-10-3188.89×2022-06-30
2023-11-30134.81×2022-09-30
2023-12-29139.44×2022-09-30
2024-01-31152.59×2022-09-30
2024-02-2962.27×2023-12-31
2024-03-2864.41×2023-12-31
2024-04-3067.59×2023-12-31
2024-05-3171.07×2023-12-31
2024-06-2872.43×2023-12-31
2024-07-3169.48×2023-12-31
2024-08-3066.37×2024-06-30
2024-09-3068×2024-06-30
2024-10-3168.18×2024-06-30
2024-11-2975.21×2024-09-30
2024-12-3174.1×2024-09-30
2025-01-3184.91×2024-09-30
2025-02-2883.46×2024-12-31
2025-03-3181.12×2024-12-31
2025-04-3082.72×2024-12-31
2025-05-3077.34×2025-03-31
2025-06-3078.92×2025-03-31
2025-07-3177.09×2025-03-31
2025-08-2962.9×2025-06-30
2025-09-3058.21×2025-06-30
2025-10-3160.05×2025-06-30
2025-11-2854.43×2025-09-30
2025-12-3151.09×2025-09-30
2026-01-3050.12×2025-09-30
2026-02-2739.67×2025-12-31
2026-03-3132.39×2025-12-31
2026-04-3029.74×2025-12-31
2026-05-2920.26×2026-03-31
2026-06-3017.9×2026-03-31
2026-07-3119.6×2026-03-31
2026-08-3119.38×2026-06-30
2026-09-2517.63×2026-06-30
Mean 66.23×Median 62.15×72% below median

ROIC

% · Annual / TTM

11.12%
Boston Scientific ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q15.26%
FY 2011 Q25.49%
FY 2011 Q35.01%
FY 2011 Q43.9%
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q41.18%
FY 2018 Q11.26%
FY 2018 Q24.81%
FY 2018 Q35.37%
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q34.21%
FY 2021 Q44.98%
FY 2022 Q14.76%
FY 2022 Q24.82%
FY 2022 Q34.35%
FY 2022 Q44.09%
FY 2023 Q14.19%
FY 2023 Q24.15%
FY 2023 Q35.35%
FY 2023 Q47.04%
FY 2024 Q17.39%
FY 2024 Q27.6%
FY 2024 Q37.23%
FY 2024 Q47.01%
FY 2025 Q17.57%
FY 2025 Q28.46%
FY 2025 Q39.32%
FY 2025 Q49.31%
FY 2026 Q110.5%
FY 2026 Q211.12%

Capital allocation

% of tracked cash uses

$390M
Boston Scientific capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q2100% · $74M0% · $0MUnavailableUnavailableUnavailable100% · $74M
FY 2009 Q328.8% · $91M0% · $0MUnavailableUnavailable71.2% · $225M100% · $316M
FY 2009 Q43.98% · $87M0% · $0MUnavailableUnavailable96.02% · $2,100M100% · $2,187M
FY 2010 Q1100% · $70MUnavailableUnavailableUnavailable0% · $0M100% · $70M
FY 2010 Q26.35% · $61MUnavailableUnavailableUnavailable93.65% · $900M100% · $961M
FY 2010 Q3100% · $78MUnavailableUnavailableUnavailable0% · $0M100% · $78M
FY 2010 Q49.5% · $63MUnavailableUnavailableUnavailable90.5% · $600M100% · $663M
FY 2011 Q17.35% · $69M39.4% · $370MUnavailableUnavailable53.25% · $500M100% · $939M
FY 2011 Q29.96% · $83M0% · $0MUnavailableUnavailable90.04% · $750M100% · $833M
FY 2011 Q326.44% · $69M0% · $0M73.56% · $192MUnavailable0% · $0M100% · $261M
FY 2011 Q421.67% · $83M0% · $0M78.33% · $300MUnavailable0% · $0M100% · $383M
FY 2012 Q132.35% · $66MUnavailable67.65% · $138MUnavailableUnavailable100% · $204M
FY 2012 Q231.71% · $52MUnavailable68.29% · $112MUnavailableUnavailable100% · $164M
FY 2012 Q315.54% · $46M0% · $0M84.46% · $250MUnavailable0% · $0M100% · $296M
FY 2012 Q415.7% · $62M58.73% · $232M25.32% · $100MUnavailable0.25% · $1M100% · $395M
FY 2013 Q134.64% · $53M0% · $0M65.36% · $100MUnavailableUnavailable100% · $153M
FY 2013 Q233.77% · $51M0% · $0M66.23% · $100MUnavailableUnavailable100% · $151M
FY 2013 Q33.6% · $57M0% · $0M4.74% · $75MUnavailable91.66% · $1,450M100% · $1,582M
FY 2013 Q414.41% · $84M47% · $274M38.59% · $225MUnavailable0% · $0M100% · $583M
FY 2014 Q130.73% · $59M4.17% · $8M65.1% · $125MUnavailableUnavailable100% · $192M
FY 2014 Q250.39% · $65M49.61% · $64M0% · $0MUnavailableUnavailable100% · $129M
FY 2014 Q311.89% · $56M88.11% · $415M0% · $0MUnavailable0% · $0M100% · $471M
FY 2014 Q4100% · $79MUnavailable0% · $0MUnavailable0% · $0M100% · $79M
FY 2015 Q1100% · $46M0% · $0M0% · $0MUnavailableUnavailable100% · $46M
FY 2015 Q242.2% · $46M57.8% · $63M0% · $0MUnavailableUnavailable100% · $109M
FY 2015 Q34.24% · $70M95.76% · $1,579M0% · $0MUnavailable0% · $0M100% · $1,649M
FY 2015 Q425.99% · $85M28.13% · $92M0% · $0MUnavailable45.87% · $150M100% · $327M
FY 2016 Q1100% · $60MUnavailableUnavailableUnavailable0% · $0M100% · $60M
FY 2016 Q223.78% · $78MUnavailableUnavailableUnavailable76.22% · $250M100% · $328M
FY 2016 Q350.35% · $71M49.65% · $70MUnavailableUnavailable0% · $0M100% · $141M
FY 2016 Q433.07% · $167M66.93% · $338MUnavailableUnavailable0% · $0M100% · $505M
FY 2017 Q130.94% · $112M0% · $0MUnavailableUnavailable69.06% · $250M100% · $362M
FY 2017 Q28.4% · $68M48.4% · $392MUnavailableUnavailable43.21% · $350M100% · $810M
FY 2017 Q313.04% · $60M0% · $0MUnavailableUnavailable86.96% · $400M100% · $460M
FY 2017 Q431.98% · $79M68.02% · $168MUnavailableUnavailable0% · $0M100% · $247M
FY 2018 Q18.94% · $60M1.34% · $9MUnavailableUnavailable89.72% · $602M100% · $671M
FY 2018 Q215.32% · $74M84.68% · $409MUnavailableUnavailable0% · $0M100% · $483M
FY 2018 Q312.14% · $76M87.86% · $550MUnavailableUnavailable0% · $0M100% · $626M
FY 2018 Q418.09% · $106M81.91% · $480MUnavailableUnavailable0% · $0M100% · $586M
FY 2019 Q13.39% · $63M17.3% · $321MUnavailableUnavailable79.31% · $1,472M100% · $1,856M
FY 2019 Q217.07% · $91M82.93% · $442MUnavailableUnavailable0% · $0M100% · $533M
FY 2019 Q33.24% · $121M96.76% · $3,619MUnavailableUnavailable0% · $0M100% · $3,740M
FY 2019 Q48.18% · $186M0% · $0MUnavailable0% · $0M91.82% · $2,088M100% · $2,274M
FY 2020 Q1100% · $100M0% · $0MUnavailable0% · $0MUnavailable100% · $100M
FY 2020 Q295.77% · $68M4.23% · $3MUnavailable0% · $0MUnavailable100% · $71M
FY 2020 Q377.78% · $49M0% · $0MUnavailable22.22% · $14MUnavailable100% · $63M
FY 2020 Q491.91% · $159M0% · $0MUnavailable8.09% · $14MUnavailable100% · $173M
FY 2021 Q19.43% · $75M88.81% · $706MUnavailable1.76% · $14MUnavailable100% · $795M
FY 2021 Q288.33% · $106M0% · $0MUnavailable11.67% · $14MUnavailable100% · $120M
FY 2021 Q37.49% · $107M91.53% · $1,308MUnavailable0.98% · $14MUnavailable100% · $1,429M
FY 2021 Q450.86% · $266M46.65% · $244MUnavailable2.49% · $13MUnavailable100% · $523M
FY 2022 Q17.53% · $121M91.59% · $1,471MUnavailable0.87% · $14MUnavailable100% · $1,606M
FY 2022 Q288.24% · $105M0% · $0MUnavailable11.76% · $14MUnavailable100% · $119M
FY 2022 Q363.83% · $150M30.21% · $71MUnavailable5.96% · $14MUnavailable100% · $235M
FY 2022 Q494.22% · $212M0% · $0MUnavailable5.78% · $13MUnavailable100% · $225M
FY 2023 Q122.2% · $111M75% · $375MUnavailable2.8% · $14MUnavailable100% · $500M
FY 2023 Q217.88% · $143M80.38% · $643MUnavailable1.75% · $14MUnavailable100% · $800M
FY 2023 Q3100% · $190M0% · $0MUnavailable0% · $0MUnavailable100% · $190M
FY 2023 Q425.19% · $267M74.81% · $793MUnavailable0% · $0MUnavailable100% · $1,060M
FY 2024 Q179.2% · $179M20.8% · $47MUnavailable0% · $0MUnavailable100% · $226M
FY 2024 Q276.35% · $155M23.65% · $48MUnavailable0% · $0MUnavailable100% · $203M
FY 2024 Q313.71% · $179M86.29% · $1,127MUnavailable0% · $0MUnavailable100% · $1,306M
FY 2024 Q47.5% · $277M92.5% · $3,418MUnavailable0% · $0MUnavailable100% · $3,695M
FY 2025 Q143.9% · $187M56.1% · $239MUnavailableUnavailableUnavailable100% · $426M
FY 2025 Q213.46% · $157M86.54% · $1,009MUnavailableUnavailableUnavailable100% · $1,166M
FY 2025 Q341.42% · $181M58.58% · $256MUnavailableUnavailableUnavailable100% · $437M
FY 2025 Q479.77% · $351M20.23% · $89MUnavailableUnavailableUnavailable100% · $440M
FY 2026 Q125.29% · $177M74.71% · $523MUnavailableUnavailableUnavailable100% · $700M
FY 2026 Q250% · $195M50% · $195MUnavailableUnavailableUnavailable100% · $390M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Boston Scientific.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources